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Abstract 
Background: Hypertriglyceridemic waist (HTGW), which incorporates measures of waist circumference and levels 
of triglyceride in blood, could act as an early-stage predictor to identify the individuals at high-risk for subclinical 
atherosclerosis. Previous studies have explored the cross-sectional association between HTGW and atherosclerosis; 
however, understanding how this association might change over time is necessary. This study will assess the associa-
tion between HTGW with 5-year subclinical carotid atherosclerosis.
Methods: 517 participants of Aboriginal, Chinese, European, and South Asian ethnicities were examined for baseline 
HTGW and 5-year indices of subclinical atherosclerosis (intima media thickness (mm), total area  (mm2), and plaque 
presence). Family history of cardiovascular disease, sociodemographic measures (age, sex, ethnicity, income level, 
maximum education), and traditional risk factors (systolic blood pressure, smoking status, total cholesterol, high-den-
sity lipoprotein cholesterol, body mass index) were incorporated into the models of association. These models used 
multiple linear regression and logistic regression.
Results: Baseline HTGW phenotype is a statistically significant and clinically meaningful predictor of 5-year intima 
media thickness (β = 0.08 [0.04, 0.11], p < 0.001), total area (β = 0.20 [0.07, 0.33], p = 0.002), and plaque presence 
(OR = 2.17 [1.13, 4.19], p = 0.02) compared to the non-HTGW group independent of sociodemographic factors and 
family history. However, this association is no longer significant after adjusting for the traditional risk factors of athero-
sclerosis (p = 0.27, p = 0.45, p = 0.66, respectively). Moreover, change in status of HTGW phenotype does not correlate 
with change in indices of atherosclerosis over 5 years.
Conclusions: Our results suggest that when the traditional risk factors of atherosclerosis are known, HTGW may not 
offer additional value as a predictor of subclinical atherosclerosis progression over 5 years.
Keywords: Atherosclerotic plaque, Ethnicity, Hypertriglyceridemic waist, Intima-media thickness, Sub-clinical 
atherosclerosis, Total area, Multi-ethnic, Longitudinal
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Background
Cardiovascular diseases (CVDs) are the leading cause 
of morbidity and mortality globally and the underlying 
contributor to this burden is mainly atherosclerosis [1]. 
The pathophysiology of atherosclerosis is well known 
and progression can be slow, sometimes beginning in 
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childhood and progressing at varying levels of pace into 
adulthood prior to mediating clinical, ischemic events 
[2].
A major risk factor for atherosclerosis is visceral obe-
sity that may increase atherosclerosis through metabolic 
changes which drive the processes of inflammation and 
fat deposition [3, 4]. Hypertriglyceridemic waist (HTGW) 
phenotype is a surrogate marker of visceral obesity [5]. 
Since this phenotype consists of measures of hypertri-
glyceridemia and elevated waist circumference it can also 
be used as an inexpensive screening tool to identify indi-
viduals at high risk for CVDs. It has been theorized that 
accumulation of adipose tissue and level of triglyceride 
present in the blood are chiefly implicated in the risk for 
atherosclerosis [3]. Though the role of triglyceride levels 
in the causation of atherosclerosis is still subject of much 
debate in the scientific community [6]. Nevertheless, 
HTGW could possibly act as a way to identify individuals 
at high-risk for subclinical atherosclerosis.
Hypertriglyceridemic waist (HTGW) is primarily a 
marker of atherogenic metabolic triad which is con-
stituted of hyperinsulinemia, hyperapolipoprotein B, 
and small LDL particles [7]. The HTGW phenotype has 
been shown to be a good predictor of increased visceral 
adiposity [8]. This phenotype has also previously been 
associated with atherosclerosis [9], abnormal coronary 
angiography [7, 10, 11], and prospective studies have 
found HTGW to be a predictor of coronary heart disease 
[12, 13].
A few studies have previously explored the cross-sec-
tional association between HTGW and atherosclerosis 
[9]; however, given atherosclerosis is known to develop 
over time, understanding how this association might 
change is necessary. Therefore, the purpose of this sub-
study was to assess the association between baseline 
hypertriglyceridemic waist and subclinical carotid ath-
erosclerosis 5 years later using indices of IMT and plaque 
presence in a multi-ethnic population of men and women 
with no pre-existing cardiovascular diseases.
Methods
Study design
The current investigation is a secondary analysis of the 
data collected as part of the Multicultural Community 
Health Assessment Trial (M-CHAT) [14]. The objective 
of the M-CHAT study was to examine the relationship 
between obesity and risk for CVD among different ethnic 
groups. The current investigation curated and analyzed 
a subset of data from the M-CHAT study to investigate 
correlations between baseline HTGW and 5-year indices 
of atherosclerosis.
The M-CHAT study was an observational prospective 
cohort which followed 517 individuals from Aboriginal, 
Chinese, European, and South Asian ethnicities for 
5  years between 2004 and 2010. Baseline and follow-up 
data were collected on measures of subclinical athero-
sclerosis (intima media thickness, presence of plaque 
and total area), family history of CVD, sociodemographic 
measures (age, sex, ethnicity, income level, maximum 
education), and traditional risk factors of atherosclerosis 
(systolic blood pressure, smoking status, total cholesterol, 
high-density lipoprotein cholesterol (HDL-C), body mass 
index (BMI)).
Setting and participants
The M-CHAT study used a convenience sampling strat-
egy. Participants were enrolled from Aboriginal (reserve 
and non-reserve), Chinese (China, Hong Kong, Taiwan), 
European (continental Europe, Ireland, and United King-
dom), and South Asian (Bangladesh, India, Nepal, Paki-
stan, and Sri Lanka) communities living in, and around, 
Vancouver, Canada. Participants were recruited by using 
advertisements in targeted community media (television, 
radio, print) and posters and brochures at community 
areas of gatherings and community health fairs. A total 
of 813 participants between the ages of 30 and 65 years 
were recruited across different levels of BMI (18.5–24.9, 
25–29.9, and > 30  kg/m2). The exclusion criteria used 
in this study were: self-reported history of CVD, recent 
weight change (greater than 2  kg in 3  months prior to 
assessment date), use of medications known to affect 
CVD and type 2 diabetes risk factors (hypoglycemic, 
antihypertensive, insulin, lipid lowering, or hormone 
replacement therapy), abusing alcohol or narcotics, diag-
nosed HIV, metabolic disorders, immune deficiency con-
ditions, or significant amputations/prosthetics.
Participant assessment
At baseline, participants attended clinics where trained 
research assistants hired from the target communities 
assessed them for demographics, anthropometry, health-
related behaviours, lipids, and sub-clinical atherosclero-
sis. Smoking status was determined by a self-report as 
either never, former (not smoked for 12 months prior to 
data collection), or current smoker. The maximum edu-
cation obtained was reported as: less than high school 
graduate, high school graduate, some post-secondary 
education, post-secondary degree or diploma, or post-
graduate education. Body mass index was calculated 
as the weight (in kg) divided by the height squared (in 
meters). Annual income levels were self-reported as 
< $20,000, $20,000–$30,000, $30,000–$40,000, $50,000–
60,000, or > $60,000.
Fasting blood samples were collected and immediately 
processed for total cholesterol, HDL-C, and triglycerides 
(TG). All measurements were carried out in the same 
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clinical laboratory with standard enzymatic procedures. 
Blood pressure was recorded as the average of 5 succes-
sive measurements after 10  min of seated rest with an 
automated oscillometric office blood pressure monitor 
(VSM MedTech Ltd, Coquitlam, Canada). Blood samples 
were processed for TG using a standard protocol by the 
ADVIA 1650 analyzer (Bayer Health Care, Morristown, 
NI). Those with both elevated TG (males ≥ 2.0 mmol/L; 
females ≥ 1.5  mmol/L) and elevated waist circumfer-
ence (males ≥ 90 cm; females ≥ 85 cm) were labelled as 
HTGW [15].
After approximately 5  years, 517 (of the original 813) 
participants returned to undergo a second assessment for 
anthropometry, lipids, and subclinical atherosclerosis. All 
measurements were taken at the same clinical laboratory 
using standard procedures. The inter- and intra-assay of 
this laboratory meet the stringent criteria of the Cana-
dian Reference Foundation Laboratory.
Carotid assessment
Carotid IMT was measured bilaterally using B-mode 
ultrasound scans via 7.5  MHz to 10  MHz linear array 
transducers in the Healthy Heart Clinic at St. Paul’s Hos-
pital in Vancouver, Canada. Scans were then transferred 
to the Cardiovascular Imaging Research Core Labora-
tory at Vancouver General Hospital to be digitized for 
analysis. Each IMT measurement was taken over a 
10 mm segment in the far wall of the right and left com-
mon coronary carotid artery within 2 cm proximal to the 
carotid bulb. The regions with the thickest IMT, exclud-
ing focal lesions, were measured. Average IMT (mm) 
was calculated as the mean of the thickness of the right 
and left carotid arteries. Plaques were identified by at 
least two observers as points of focally increased thick-
ness in comparison with the IMT thickness to either 
side of the suspected area. This assessment was con-
ducted in the Cardiovascular Imaging Research Core Lab 
(CIRCL) in Vancouver, Canada. The intraclass and inter-
observer correlation values for this method were 0.922 
to 0.948 and 0.850 to 0.901, respectively [16]. Total area, 
which is a superior measure of subclinical atherosclero-
sis to IMT [16], was calculated as the sum of IMT area 
(20  mm length × average measured IMT thickness) and 
the total of all plaque areas (average of all plaque thick-
nesses × sum of lesion lengths). Thus, average carotid 
IMT, total area (of plaque and IMT), and plaque presence 
were used as indices of subclinical atherosclerosis. For 
repeated measures in the same subject, the accuracy and 
precision were −  0.001  mm (not significant compared 
to 0.00  mm) and 0.04  mm, respectively, for IMT and 
− 0.21 mm2 (not significant compared to 0.00 mm2) and 
3.61 mm2, respectively, for total area [16].
Statistical analysis
Participants with any missing data were excluded from 
the analysis. All continuous variables were tested for nor-
mality. Non-normal variables were reported as median 
plus interquartile range. Normal variables were reported 
as mean plus standard deviation. Non-normal variables 
were log transformed before analysis using the natural 
logarithm. Categorial variables were reported as numbers 
and percentages. One-way ANOVA and chi-square tests 
were used to examine the differences in baseline charac-
teristics between participants in different categories of 
HTGW phenotype (none, elevated TG only, elevated WC 
only, HTGW). Independent t test and chi-square were 
used to explore the differences in baseline characteristics 
between males and females, and the differences in base-
lines characteristics between participants who completed 
the 5-year follow up and those who did not. Point-Biserial 
coefficient and logistic regression were used to assess the 
bivariate correlation between baseline HTGW categories 
with 5-year IMT, total area and plaque presence.
Multiple linear regression analysis was used to cre-
ate models to examine the relationship between base-
line HTGW categories with 5-year IMT and total area. 
Assumptions of multivariate normality, non-multicol-
linearity, non-autocorrelation, and homoscedasticity 
were checked. Logistic regression analysis was also used 
to create other models that examined the association 
between baseline HTGW categories with 5-year plaque 
presence. Non-HTGW phenotype was used as the ref-
erence group. For both analyses, two models (A and B) 
were created. Model A adjusted for age, sex, ethnicity, 
maximum education, income level, and family history 
of CVD. Model B adjusted for all variables in model A 
as well as BMI, smoking status, total cholesterol, HDL-
C, and systolic blood pressure. Significance level 0.05 was 
used throughout this study. Statistical analysis was per-
formed using IBM SPSS Statistics version 24.0 (SPSS Inc, 
Chicago, IL).
Results
A total of 517 of 813 participants (63%) recruited at base-
line completed the 5-year follow-up assessment. The 
main reasons for not completing the study were lost-to-
follow-up in which the participant’s contact informa-
tion was no longer valid and refusal to participate due to 
lack of interest. Completers were older (p = 0.008), had 
a lower BMI (p = 0.005), waist circumference (p < 0.001), 
less likely to have HTGW (p < 0.001), be a current smoker 
(p < 0.001), be Aboriginal (p < 0.001), but more likely to 
have a higher education (p < 0.001) and a higher income 
(p < 0.001) than non-completers (Additional file  1: 
Table S1).
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Table  1 outlines the baseline characteristics of the 
study participants by HTGW components. Signifi-
cant differences were observed for ethnicity (p < 0.001), 
BMI (p < 0.001), total cholesterol (p < 0.001), HDL-C 
(p < 0.001), systolic blood pressure (p < 0.001) and smok-
ing status (p < 0.001) by HTGW phenotype. The preva-
lence of current smokers was greater in the HTGW 
group. Baseline IMT and total area also varied signifi-
cantly by HTGW whereas plaque presence did not.
Presence of baseline HTGW phenotype was weakly, 
but positively correlated with 5-year IMT  (rpb = 0.11, 
p = 0.02), total area  (rpb = 0.13, p = 0.00), and plaque 
presence (2.06 (1.13, 3.74), p = 0.02). Additionally, a sig-
nificant inverse association was observed between the 
presence of elevated TG phenotype at baseline with the 
5-year total area  (rpb = − 0.11, p = 0.01) (Additional file 1: 
Table  S2). However, this association was not significant 
when adjusting for sociodemographic and traditional risk 
factors in Table 2. When adjusting for sociodemographic 
factors (age, sex, ethnicity, income level, maximum edu-
cation) and family history in model A, a statistically and 
clinically significant association was observed between 
Table 1 Baseline characteristics of the study population stratified by presence of HTGW components
Categorical variables presented as n (%). Normally distributed continuous variables presented as mean ± SD
CVD cardiovascular disease, MET metabolic equivalent, BMI body mass index, HDL-C high-density lipoprotein cholesterol, HTGW hypertriglyceridemic waist, WC waist 
circumference, TG triglycerides
Characteristic Non-HTGW 
(Healthy) (n = 312)
Elevated WC (n = 254) Elevated TG (n = 91) HTGW (n = 156) Significance 
(p value)
Age 46.9 ± 8.8 46.9 ± 8.5 46.9 ± 9.1 45.5 ± 8.8 0.36
Sex
 Male 138 (44.2%) 137 (53.9%) 33 (36.3%) 84 (53.8%) 0.006
Ethnicity < 0.001
 Aboriginal 37 (11.9%) 89 (35.0%) 14 (15.4%) 47 (30.1%)
 Chinese 113 (36.2%) 40 (15.7%) 42 (46.2%) 25 (16.0%)
 European 88 (28.2%) 68 (26.8%) 7 (7.7%) 38 (24.4%)
 South Asian 74 (23.7%) 57 (22.4%) 28 (30.8%) 46 (29.5%)
Family history of CVD present (%) 149 (47.8%) 113 (44.5%) 43 (47.3%) 71 (45.5%) 0.88
Maximum education 0.002
 Less than high school 27 (8.7%) 40 (15.7%) 6 (6.6%) 23 (14.7%)
 High school graduate 62 (64.5%) 46 (18.1%) 29 (31.9%) 31 (19.9%)
 Some post-secondary education 35 (11.2%) 48 (18.9%) 10 (11.0%) 24 (15.4%)
 Post-secondary degree/diploma 133 (42.6%) 94 (37.0%) 39 (42.9%) 53 (34.0%)
 Post graduate education 55 (17.6%) 25 (9.8%) 7 (7.7%) 24 (15.4%)
Annual income level 0.099
 < $20,000 36 (11.5%) 36 (14.2%) 14 (15.4%) 24 (15.4%)
 $20,000–$30,000 40 (12.8%) 33 (13.0%) 11 (12.1%) 21 (13.5%)
 $30,000–$40,000 35 (11.2%) 40 (15.7%) 16 (17.6%) 29 (18.6%)
 $40,000–$50,000 40 (12.8%) 25 (9.8%) 9 (9.9%) 25 (16.0%)
 $50,000–$60,000 42 (13.5%) 17 (6.7%) 12 (13.2%) 12 (7.7%)
 > $60,000 115 (36.9%) 95 (37.4%) 28 (30.8%) 44 (28.2%)
Smoking < 0.001
 Never smoker 215 (68.9%) 140 (55.1%) 68 (74.7%) 79 (50.6%)
 Former smoker 77 (24.7%) 87 (34.3%) 15 (16.5%) 48 (30.8%)
 Current smoker 20 (6.4%) 27 (10.6%) 8 (8.8%) 29 (18.6%)
Body mass index (kg/m2) 24.0 ± 2.8 30.3 ± 4.0 25.1 ± 2.2 31.3 ± 4.4 < 0.001
Total cholesterol (mmol/L) 5.09 ± 0.99 5.00 ± 0.89 5.73 ± 1.07 5.63 ± 0.91 < 0.001
HDL-C (mmol/L) 1.45 ± 0.36 1.26 ± 0.31 1.19 ± 0.35 1.08 ± 0.28 < 0.001
Systolic blood pressure (mm HG)a 112 [105, 120] 119 [111, 127] 115 [107, 124] 120 [114, 129] < 0.001
Intima media thickness (mm)a 0.63 [0.58, 0.71] 0.67 [0.60, 0.76] 0.64 [0.59, 0.72] 0.67 [0.60, 0.75] 0.001
Total area  (mm2)a 14.62 [12.20, 21.05] 16.60 [13.10, 25.31] 15.47 [11.90, 24.36] 17.60 [13.50, 23.54] 0.01
Presence of plaque 154 (49.4%) 133 (52.4%) 45 (49.5%) 96 (61.5%) 0.08
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the presence of HTGW phenotype with average IMT 
(0.08 [0.04, 0.11], p < 0.001), total area (0.20 [0.07, 0.33], 
p = 0.002), and plaque presence (OR = 2.17 [1.13, 4.19], 
p = 0.02) compared to the non-HTGW group (Table  2). 
Presence of elevated WC at baseline was also positively 
associated with 5-year IMT outcome (0.05 [0.02, 0.09], 
p = 0.002) compared to the non-HTGW group. Upper 
limits of normal for average IMT and total area are 
roughly 0.9 mm and 18.3  mm2, respectively [16]. When 
adjusting for traditional risk factors of atherosclerosis 
(BMI, smoking status, total cholesterol, HDL-C, and sys-
tolic blood pressure systolic blood pressure) and sociode-
mographic factors in model B, we found no significance 
between elevated WC, elevated TG, and HTGW pheno-
types with indices of atherosclerosis, compared to the 
non-HTGW group. We also investigated the change in 
standardized β for the variables in each linear regression 
model (Additional file 1: Table S3) and found that com-
pared to model A, HTGW phenotype was not significant 
in model B but total cholesterol and systolic blood pres-
sure were significant. Total cholesterol and systolic blood 
pressure were associated with average IMT (std. β = 0.09, 
p = 0.03; std. β = 0.12, p = 0.003), total area (std. β = 0.19, 
p < 0.001; std. β = 0.12, p = 0.01), and plaque presence 
(OR = 1.52, p < 0.001; OR = 1.28, p = 0.05) in model B. 
Total cholesterol and systolic blood pressure may be 
largely mediating the association between elevated WC 
and HTGW phenotypes with IMT, the effect of HTGW 
with total area, and the effect of HTGW with plaque 
presence.
Next, we examined whether there was a correlation 
between change in HTGW phenotypes with change in 
the indices of subclinical atherosclerosis over 5  years. 
The status of change in HTGW phenotypes was catego-
rized into four different groups of (1) Without HTGW 
at Baseline and Follow-up (N = 376); (2) With HTGW at 
Baseline and Follow-up (N = 49); (3) Acquired HTGW 
(N = 50); (4) Reversed HTGW (N = 37). We found that all 
groups had a significant increase in IMT, total area, and 
plaque presence in proportions that were similar between 
groups (IMT p = 0.99; total area p = 0.35; plaque presence 
p = 0.06) (Table 3). The only exception was the group that 
Reversed HTGW. This group showed no change in the 
proportion of participants with plaques present (73.0%). 
Adjustments for sociodemographic and traditional risk 
factors did not change these findings (Additional file  1: 
Table S4 and S5).
Furthermore, the regression models A and B were run a 
second time for all atherosclerosis indices while control-
ling for the baseline reading of each index (Table 4). We 
observed no significant associations between any of the 
baseline HTGW phenotypes with any of the 5-year indi-
ces of atherosclerosis when controlling for the baseline 
readings of each index.
Discussion
This study assessed the relationship between hyper-
triglyceridemic waist (HTGW) at baseline with 5-year 
indicators of subclinical atherosclerosis in a multi-ethnic 
cohort. Our findings indicate that HTGW phenotype is 
a statistically significant and clinically meaningful pre-
dictor of 5-year subclinical atherosclerosis measures 
of IMT, total area, and plaque presence independent of 
sociodemographic factors and family history. However, 
this effect appears to be mediated largely by known risk 
factors based on our finding that when adjusting for 
Table 2 The association of HTGW phenotype components with 5-year subclinical carotid artery atherosclerosis indices
Outcome variables are in ln(x) form; amultiple linear regression; b logistic regression; Model A adjusts for age, maximum education, sex, family history, ethnicity, and 
income level; Model B adjusts for all variables adjusted for in model A plus: BMI, smoking status, total cholesterol, HDL-C, systolic blood pressure; Elevated waist 
circumference (WC) was ≥ 85 cm in women and ≥ 90 cm in men; Elevated triglycerides (TG) were ≥ 1.5 mmol/L in women and ≥ 2 mmol/L in men; HTGW is the 
presence of both elevated WC and TG; BMI body mass index, HDL-C high-density lipoprotein cholesterol, HTGW hypertriglyceridemic waist, WC waist circumference, 
TG triglycerides
Intima media  thicknessa Total  areaa Plaque  presenceb
β (95% CI) p value β (95% CI) p value OR (95% CI) p value
Model A
 Non-HTGW Reference Reference Reference Reference Reference Reference
 Elevated WC 0.05 (0.02, 0.09) 0.002 0.05 (− 0.06, 0.16) 0.33 1.03 (0.62, 1.69) 0.92
 Elevated TG 0.02 (− 0.03, 0.07) 0.39 − 0.02 (− 0.17, 0.14) 0.85 0.78 (0.40, 1.50) 0.46
 HTGW 0.08 (0.04, 0.11) < 0.001 0.20 (0.07, 0.33) 0.002 2.17 (1.13, 4.19) 0.02
Model B
 Non-HTGW Reference Reference Reference Reference Reference Reference
 Elevated WC 0.02 (− 0.02, 0.07) 0.24 0.02 (− 0.11, 0.16) 0.76 0.81 (0.42, 1.56) 0.53
 Elevated TG 0.00 (− 0.05, 0.05) 0.94 − 0.12 (− 0.28, 0.04) 0.14 0.51 (0.24, 1.07) 0.08
 HTGW 0.03 (− 0.02, 0.08) 0.27 0.06 (− 0.10, 0.22) 0.45 1.21 (0.53, 2.75) 0.66
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traditional risk factors (total cholesterol and systolic 
blood pressure), this association was not significant.
Our findings are congruent with the cross-sectional 
studies conducted in a diverse range of other asympto-
matic populations including Caucasian men [17], multi-
ethnic populations (Aboriginal, Chinese, European, 
South Asian) [9], Canadian Cree [18], patients with 
chronic kidney disease [19], patients living with type 
2 diabetes [8], and subjects with cardiometabolic risk 
factors [20] that found a positive correlation between 
HTGW and subclinical atherosclerosis. In the total area 
and plaque presence models, presence of elevated WC or 
elevated TG alone did not correlate with higher total area 
or higher proportion with plaque presence. However, 
the presence of both of these phenotypes (i.e., HTGW 
phenotype) was correlated with greater total area and a 
higher proportion with plaque presence. This observa-
tion suggests a synergistic elevation of risk. This theory is 
in line with previous cross-sectional findings in the same 
multi-ethnic sample that found a stronger correlation 
between HTGW with subclinical atherosclerosis than 
between elevated TG and elevated WC individually with 
subclinical atherosclerosis [9]. Indeed, the HTGW phe-
notype has been shown to be associated with increased 
risk of cardiometabolic diseases [21–30]. Addition-
ally, multiple studies have reported an elevated risk of 
Table 3 Comparing within- and  between- HTGW group differences for  atherosclerosis outcome measures 
without adjusting any covariates
Categorical variables presented as n (%). Continuous variables presented as mean ± SD. Paired-samples t test used to test within-group differences for continuous 
variables. McNemar tests used to test within-group differences for categorical variables. ANCOVA used to test between-group differences for continuous variables. For 
this test, the follow-up assessment was used as the outcome variable and the baseline variable was controlled for. Chi-square used to test between-group differences 
for categorical variables. To test between group variables, change in plaque presence was considered in four groups of no change absence of plaque, no change 
presence of plaque, acquired plaque, plaque reversed. *Marks a significant difference with the corresponding baseline measurement at 0.01 cut-off. Elevated waist 
circumference (WC) was ≥ 85 cm in women and ≥ 90 cm in men. Elevated triglycerides (TG) were ≥ 1.5 mmol/L in women and ≥ 2 mmol/L in men. HTGW is the 
presence of both elevated WC and TG. Acquired HTGW refers to those with no HTGW at baseline who tested positive in the follow-up assessment. HTGW reversed, 
inversely, refers to those with HTGW at baseline who tested negative in the follow-up assessment
Without HTGW at baseline 
and follow-up (N = 376)
With HTGW at baseline 
and follow-up (N = 49)
Acquired HTGW (N = 50) Reversed HTGW (N = 37) Between-
group 
differences
Baseline 5 year Baseline 5 year Baseline 5 year Baseline 5 year p value
IMT (mm) 0.67 ± 0.12 0.72 ± 0.14* 0.71 ± 0.12 0.77 ± 0.14* 0.65 ± 0.09 0.70 ± 0.11* 0.70 ± 0.13 0.75 ± 0.16* 0.99
Total area 
 (mm2)




200 (53.2%) 252 (67.0%)* 30 (61.2%) 42 (85.7%)* 25 (50.0%) 34 (68.0%)* 27 (73.0%) 27 (73.0%) 0.06
Table 4 Association of  HTGW phenotypes with  5-year subclinical atherosclerosis indices while  adjusting for  each 
baseline index
Outcome variables are in ln(x) form; a multiple linear regression; b logistic regression; Model A adjusts for age, maximum education, sex, family history, ethnicity, 
and income level; Model B adjusts for all variables adjusted for in model A plus: BMI, smoking status, total cholesterol, HDL-C, systolic blood pressure; Elevated waist 
circumference (WC) was ≥ 85 cm in women and ≥ 90 cm in men; Elevated triglycerides (TG) were ≥ 1.5 mmol/L in women and ≥ 2 mmol/L in men; HTGW is the 
presence of both elevated WC and TG; BMI body mass index, HDL-C high-density lipoprotein cholesterol, HTGW hypertriglyceridemic waist, WC waist circumference, 
TG triglycerides
Intima media  thicknessa Total  areaa Plaque  presenceb
β (95% CI) p value β (95% CI) p value OR (95% CI) p value
Model A
 Non-HTGW Reference Reference Reference Reference Reference Reference
 Elevated WC 0.02 (0.00, 0.03) 0.10 0.05 (− 0.03, 0.12) 0.22 1.34 (0.71, 2.52) 0.36
 Elevated TG 0.02 (− 0.01, 0.05) 0.14 − 0.01 (− 0.11, 0.09) 0.86 0.87 (0.38, 2.00) 0.74
 HTGW 0.02 (− 0.01, 0.04) 0.18 0.08 (0.00, 0.16) 0.06 2.04 (0.91, 4.58) 0.09
Model B
 Non-HTGW Reference Reference Reference Reference Reference Reference
 Elevated WC 0.01 (− 0.01, 0.03) 0.36 0.02 (− 0.07, 0.11) 0.68 1.33 (0.59, 2.99) 0.49
 Elevated TG 0.02 (− 0.01, 0.04) 0.30 − 0.06 (− 0.16, 0.05) 0.30 0.66 (0.26, 1.68) 0.38
 HTGW 0.01 (− 0.02, 0.04) 0.58 0.01 (− 0.10, 0.12) 0.82 1.48 (0.53, 4.11) 0.46
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diabetes [31–40] and cardiovascular diseases [12, 41–46] 
among individuals with HTGW, highlighting the poten-
tial value of this phenotype as a marker of CVD risk fac-
tors and poor outcomes.
Change in HTGW phenotypes did not correlate with 
change in indices of subclinical atherosclerosis over 
5 years. Hence, acquisition or reversal of HTGW cannot 
be used as reliable tool to track one’s risk level for athero-
sclerosis. Within the group that experienced a reversal in 
their HTGW phenotype, we observed a 5-year halt in the 
proportion of participants that presented with plaques. 
This observation indicates that lifestyle measures and 
reversal of HTGW may be beneficial. However, we did 
not observe a halt in the progression of IMT or total 
area in this group. This leads us to hypothesize that the 
mechanism for increasing IMT and total area might be 
different from the mechanism for increasing plaque pres-
ence which accounts for the difference in associations. 
This difference in underlying mechanisms would likely be 
independent of the variables that were adjusted for in our 
models as our adjustments did not affect this observa-
tion. Furthermore, baseline HTGW phenotypes were not 
associated with 5-year change in indices of atherosclero-
sis. This finding indicates that whether a patient has any 
of the HTGW phenotypes does not impact the progres-
sion of their atherosclerosis over 5 years.
The strength of our study lies in exploring the rela-
tionship between HTGW and subclinical atheroscle-
rosis longitudinally. The ethnic and sociodemographic 
diversity in our study population allowed us to establish 
a significantly positive correlation between HTGW with 
subclinical atherosclerosis that shows independence 
from income level, maximum education, and ethnic-
ity. Another strength of this study is in using multiple 
markers of subclinical atherosclerosis (IMT, total area, 
and presence of plaques) and utilization of carotid ultra-
sound which have allowed for a robust and direct meas-
ure of atherosclerosis, sensitive enough to detect early 
atherogenesis.
The original study adopted a purposeful sampling strat-
egy which stratified participants by ethnicity and sex and 
ensured equal representation from each group and may 
not be representative of the general population. The eth-
nicities represented in our sample are Aboriginal, Chi-
nese, South Asian, and European communities. Hence, 
the findings of this paper may not hold valid in other eth-
nic groups. Furthermore, our assessments did not take 
into account the fact that categorical assessments of ele-
vated waist circumference may require different cut-offs 
by ethnicity. Our sample was also limited to individuals 
between the ages of 30 and 65 years. Hence, the associa-
tion between HTGW and 5-year subclinical atheroscle-
rosis outcomes in younger and older age groups might 
need to be further examined. Nevertheless, the age and 
ethnic groups represented in our sample are those that 
have been identified at high risk for CVD and should be 
targeted for screening practices. Our assessment of the 
association of HTGW phenotypes with the progression 
of atherosclerosis was limited by the fact that a signifi-
cant majority of participants already demonstrated evi-
dence of subclinical atherosclerosis at baseline. Future 
longitudinal studies assessing participants with no evi-
dence of subclinical atherosclerosis at baseline may be 
able to provide a better assessment of the association 
between HTGW phenotypes with development and pro-
gression of subclinical atherosclerosis. Furthermore, it is 
possible that the use of more detailed measurements of 
IMT, including 3D variables, could have detected more 
subtle findings. However, the use of well validated meth-
ods of carotid IMT in this study suggest that use of other 
well accepted measures of carotid atherosclerotic burden 
could not have shown different results. As a sub-study, 
the present investigation consists of secondary analysis. 
Future studies powered for the outcome may be war-
ranted. Age and gender-based classifications of IMT into 
normal versus abnormal categories [47] could provide a 
more clinically meaningful evaluation of participants. 
However, stratification of participants by age and gender 
would significantly reduce our statistical power to detect 
within and between group differences Hence, we used 
IMT as a continuous variable while adjusting for age and 
gender in our models. Due to the significant number of 
non-completers this study is subject to the possibility of 
type II error. There is also a possibility of residual con-
founding and random error in this study. Furthermore, 
while we did not adjust for medication use, only 4.6% of 
participants were taking a statin at the 5-year follow-up. 
Therefore, it is unlikely that the use of statins could have 
had a meaningful impact on our findings.
Conclusions
Our findings showed that baseline presence of HTGW 
phenotype in healthy individuals is a significant predic-
tor of 5-year subclinical atherosclerosis independent of 
sociodemographic factors and family history. However, 
this effect seems to be largely mediated by known risk 
factors (total cholesterol and systolic blood pressure) 
which are often measured at the same time as the ele-
ments of HTGW phenotype (TG and WC). Hence, utility 
of HTGW phenotype as a clinical tool remains unproven. 
Our results also indicated that the change in presence or 
absence of HTGW phenotype does not correlate with 
a change in indices of subclinical atherosclerosis over 
5 years. However, in the absence of more long term fol-
low up, data on atherosclerotic burden in other areas 
such as coronary calcium score, and clinical end points, 
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the utility of monitoring and tracking HTGW cannot be 
dismissed. Future research should examine the relation-
ship between HTGW phenotype and indices of athero-
sclerosis among individuals with manifest cardiovascular 
disease. Another important area for future research is to 
examine whether there indeed is an alternative mecha-
nism for development of plaque that is distinctively 
different from IMT and total area. Alternative measure-
ments of hypertriglyceridemic waist or new variables that 
can be independently measured outside the clinical set-
ting and provide predictive insight, can be highly impact-
ful in identification of at-risk individuals for subclinical 
atherosclerosis in a way that is cost-effective and adopt-
able in high numbers.
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